Article
Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival.
Acta neuropathologica communications - 10 Jan 2022
Ebrahimi Azadeh, Korshunov Andrey, Reifenberger Guido, Capper David, Felsberg Joerg, Trisolini Elena, Pollo Bianca, Calatozzolo Chiara, Prinz Marco, Staszewski Ori, Schweizer Leonille, Schittenhelm Jens, Harter Patrick N, Paulus Werner, Thomas Christian, Kohlhof-Meinecke Patricia, Seiz-Rosenhagen Marcel, Milde Till, Casalini Belén M, Suwala Abigail, Wefers Annika K, Reinhardt Annekathrin, Sievers Philipp, Kramm Christof M, Etminam Nima, Unterberg Andreas, Wick Wolfgang, Herold-Mende Christel, Sturm Dominik, Pfister Stefan M, Sill Martin, Jones David T W, Schrimpf Daniel, Reuss David E, Aldape Ken, Abdullaev Zied, Sahm Felix, von Deimling Andreas, Stichel Damian
Abstract excerpt
Pleomorphic xanthoastrocytoma (PXA) in its classic manifestation exhibits distinct morphological features and is assigned to CNS WHO grade 2 or grade 3. Distinction from glioblastoma variants and lower grade glial and glioneuronal tumors is a common diagnostic challenge. We compared a morphologically defined set of PXA (histPXA) with an independent set, defined by DNA methylation analysis (mcPXA). HistPXA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
